264 related articles for article (PubMed ID: 29363242)
21. Efficacy and Safety of Metronidazole Monotherapy versus Vancomycin Monotherapy or Combination Therapy in Patients with Clostridium difficile Infection: A Systematic Review and Meta-Analysis.
Li R; Lu L; Lin Y; Wang M; Liu X
PLoS One; 2015; 10(10):e0137252. PubMed ID: 26444424
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Addition of Intravenous Metronidazole to Oral Vancomycin Therapy in Critically Ill Patients with Non-Fulminant Severe Clostridioides difficile Infection.
Vega AD; Heil EL; Blackman AL; Banoub M; Kristie Johnson J; Leekha S; Claeys KC
Pharmacotherapy; 2020 May; 40(5):398-407. PubMed ID: 32246501
[TBL] [Abstract][Full Text] [Related]
23. Tigecycline for severe Clostridium difficile infection.
Thomas A; Khan F; Uddin N; Wallace MR
Int J Infect Dis; 2014 Sep; 26():171-2. PubMed ID: 25064460
[TBL] [Abstract][Full Text] [Related]
24. Characteristics and predictors of treatment failure with intravenous tigecycline monotherapy among adult patients with severe Clostridioides (Clostridium) difficile infection: a single-centre observational cohort study.
Szabo BG; Duma L; Lenart KS; Kiss R; Vad E; Petrik BR; Ostorhazi E; Kadar B
Diagn Microbiol Infect Dis; 2021 Feb; 99(2):115231. PubMed ID: 33099134
[TBL] [Abstract][Full Text] [Related]
25. Effects of tigecycline and vancomycin administration on established Clostridium difficile infection.
Theriot CM; Schumacher CA; Bassis CM; Seekatz AM; Young VB
Antimicrob Agents Chemother; 2015 Mar; 59(3):1596-604. PubMed ID: 25547352
[TBL] [Abstract][Full Text] [Related]
26. Clostridium difficile infection (CDI) severity and outcome among patients infected with the NAP1/BI/027 strain in a non-epidemic setting.
Scardina T; Labuszewski L; Pacheco SM; Adams W; Schreckenberger P; Johnson S
Infect Control Hosp Epidemiol; 2015 Mar; 36(3):280-6. PubMed ID: 25695169
[TBL] [Abstract][Full Text] [Related]
27. Fecal Microbiota Transplantation in Recurrent NAP1/B1/027 Clostridium Difficile Infection (CDI) Resistant to Vancomycin and Metronidazole in a Patient with Ulcerative Colitis (UC): A Case Report.
Preda CM; Meianu C; Sandra I; Becheanu G; Dumbrava M; Manuc M; Diculescu M
Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):563-7. PubMed ID: 30044904
[TBL] [Abstract][Full Text] [Related]
28. Best strategies in recurrent or persistent Clostridium difficile infection.
Cocanour CS
Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
[TBL] [Abstract][Full Text] [Related]
29. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.
Kimura T; Snijder R; Sugitani T
J Infect Chemother; 2019 Aug; 25(8):615-620. PubMed ID: 30987950
[TBL] [Abstract][Full Text] [Related]
30. Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection.
Bossé D; Lemire C; Ruel J; Cantin AM; Ménard F; Valiquette L
Infection; 2013 Apr; 41(2):579-82. PubMed ID: 22996384
[TBL] [Abstract][Full Text] [Related]
31. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
Johnson S; Louie TJ; Gerding DN; Cornely OA; Chasan-Taber S; Fitts D; Gelone SP; Broom C; Davidson DM;
Clin Infect Dis; 2014 Aug; 59(3):345-54. PubMed ID: 24799326
[TBL] [Abstract][Full Text] [Related]
32. Clostridium difficile infection in older adults: a review and update on its management.
Kee VR
Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
[TBL] [Abstract][Full Text] [Related]
33. [Clostridium difficile in visceral surgery].
Herzog T; Deleites C; Belyaev O; Chromik AM; Uhl W
Chirurg; 2015 Aug; 86(8):781-6. PubMed ID: 25432576
[TBL] [Abstract][Full Text] [Related]
34. Tigecycline as last resort in severe refractory Clostridium difficile infection: a case report.
Knafl D; Winhofer Y; Lötsch F; Weisshaar S; Steininger C; Burgmann H; Thalhammer F
J Hosp Infect; 2016 Mar; 92(3):296-8. PubMed ID: 26810610
[No Abstract] [Full Text] [Related]
35. Clostridium difficile infection in the "oldest" old: clinical outcomes in patients aged 80 and older.
Cober ED; Malani PN
J Am Geriatr Soc; 2009 Apr; 57(4):659-62. PubMed ID: 19392957
[TBL] [Abstract][Full Text] [Related]
36. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy.
Jardin CG; Palmer HR; Shah DN; Le F; Beyda ND; Jiang Z; Garey KW
J Hosp Infect; 2013 Sep; 85(1):28-32. PubMed ID: 23834988
[TBL] [Abstract][Full Text] [Related]
37. Clostridium difficile treatment in neutropenic patients: Clinical outcomes of metronidazole, vancomycin, combinations, and switch therapy.
Tieu JD; Schmidt SA; Miller JL; Kupiec KE; Skrepnek GH; Liu C; Smith WJ
J Oncol Pharm Pract; 2019 Apr; 25(3):520-528. PubMed ID: 29157145
[TBL] [Abstract][Full Text] [Related]
38. Differences in the rate of carbapenem-resistant Enterobacteriaceae colonisation or Clostridium difficile infection following frontline treatment with tigecycline vs. meropenem for intra-abdominal infections.
Bartoletti M; Tedeschi S; Pascale R; Raumer L; Maraolo AE; Palmiero G; Tumietto F; Cristini F; Ambretti S; Giannella M; Lewis RE; Viale P
Int J Antimicrob Agents; 2018 Mar; 51(3):516-521. PubMed ID: 29410250
[TBL] [Abstract][Full Text] [Related]
39. The efficacy of intracolonic vancomycin for severe Clostridium difficile colitis: a case series.
Akamine CM; Ing MB; Jackson CS; Loo LK
BMC Infect Dis; 2016 Jul; 16():316. PubMed ID: 27388627
[TBL] [Abstract][Full Text] [Related]
40. Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.
Pichenot M; Héquette-Ruz R; Le Guern R; Grandbastien B; Charlet C; Wallet F; Schiettecatte S; Loeuillet F; Guery B; Galperine T
Infection; 2017 Aug; 45(4):425-431. PubMed ID: 28120176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]